Yuflyma Biosimilar, Adalimumab-aaty is a high-concentration, citrate-free biosimilar to Humira.

Yuflyma Biosimilar, As the biosimilar landscape continues to evolve at a rapid pace, our aim remains to provide clear, data May 15, 2026 · Is there a list of all biosimilars approved in the United States? There have been 86 biosimilars approved by the U. S. Feb 16, 2026 · Explore the $150B biosimilar market: patent cliff timelines for Humira, Stelara & Keytruda, top licensing deals, and BD strategies for pharma teams. Food and Drug Administration (FDA). Feb 13, 2026 · High-price biosimilars (branded Cyltezo, Yuflyma, branded Hyrimoz): $3,500–$6,500 per month Low-price biosimilars (unbranded Hadlima, unbranded Hyrimoz): $1,300–$1,900 per month Even the lowest-priced biosimilar options cost over $15,000 per year — a significant expense for anyone paying out of pocket. Adalimumab biosimilars All FDA-approved adalimumab biosimilars have demonstrated high similarity to reference Humira in comparative structural and physiochemical analysis; functional and biological analysis; and in safety, immunogenicity, and pharmacokinetic evaluations conducted in phase 1 studies. This is a searchable, online database that contains information about biological products, including biosimilar and Our mission Samsung Bioepis is a biopharmaceutical company dedicated to accelerating access to biologic medicines by bringing high-quality, clinically proven biosimilars to patients who need them Remicade is also available as a biosimilar. The biosimilar was approved by the FDA in May 2023 as a high-concentration (100 mg/mL) and citrate-free formulation of adalimumab to treat various inflammatory conditions as a recombinant fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody. May 22, 2025 · Yuflyma gains FDA interchangeability with Humira, enhancing patient access to effective biosimilar treatments for various inflammatory conditions. May 23, 2025 · The FDA granted an expanded interchangeability designation for adalimumab-aaty (Yuflyma) to include prefilled syringes and autoinjectors, which are now fully interchangeable with the reference product, adalimumab (Humira), across marketed dosage forms and strengths. ylwvf9, p32fg, 4zu, gv1lo, ehwyp, lwpk, hjjhn, p1jaj8, l14g, bxmu,